Reference SummaryJorcyk CL, Prostate 1998 Jan 1;34(1):10-22
Title |
Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix. |
Authors |
Jorcyk CL; Liu ML; Shibata MA; Maroulakou IG; Komschlies KL; McPhaul MJ ; Resau JH ; Green JE |
Journal |
Prostate |
Volume |
34 |
Issue |
1 |
Year |
1998 |
Pages |
10-22 |
Abstract |
BACKGROUND. Tumor vaccines show promise as a new approach for treating cancer. We have developed a murine prostate cancer cell line which can be used to study growth factor and extracellular matrix regulation of prostate differentiation and will be useful for generating tumor vaccines using the C3(1)/T-AG transgenic model of prostate cancer. METHODS. Pr-14 cells were established in defined growth media (GM) and grown in GM, GM + 2% fetal bovine serum (FBS) or DMEM + 10% FBS on plastic, collagen, or Matrigel. Immunofluorescence and Western blot analyses were performed using antibodies to cytokeratin, vimentin, SV40 large T-antigen, and androgen receptor (BR). RESULTS. Pr-14 cells are cytokeratin-positive, vimentin- negative, and express SV40 large T-antigen. These cells are tumorigenic when injected into athymic nude mice and appear to be androgen-independent. Pr-14 cell lines are nontumorigenic when injected into syngeneic FVB/N mice, but form tumors in transgenic T-AG-expressing FVB/N mice. Cell growth and morphology are dependent on media composition which determines whether ductal or acinar structures form when grown on Matrigel. CONCLUSIONS. The mouse prostate adenocarcinoma cell line, Pr-14, undergoes alterations in the state of differentiation dependent upon serum concentration when grown on Matrigel. The Pr-14 cell line is a useful reagent to study prostate cell/extracellular matrix interactions, and for immunotherapy and cancer vaccine studies in C3(1)/T-AG transgenic mice. (C) 1998 Wiley-Liss, Inc. |
Links |
J:45372 – MGI References 9428383 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| FVB/N-Tg(C3-1-TAg)#Jeg | Prostate gland adenocarcinoma | Prostate gland |
observed |